Higher burden of cardiometabolic and socioeconomic risk factors in women with type 2 diabetes: an analysis of the Glycemic Reduction Approaches in Diabetes (GRADE) baseline cohort
Source : https://drc.bmj.com/content/11/2/e003159
Introduction Type 2 diabetes mellitus (T2DM) is a powerful risk factor for cardiovascular disease (CVD), conferring a greater relative risk in women than men. We sought to examine sex differences...
Conclusions: This contemporary cohort demonstrates that women with T2DM continue to have a greater burden of cardiometabolic and socioeconomic risk factors than men, particularly younger women. Attention to these persisting disparities is needed to reduce the burden of CVD in women.
Share
A Comprehensive Review on Weight Loss Associated with Anti-Diabetic Medications
Source : https://www.mdpi.com/2075-1729/13/4/1012
Obesity is a complex metabolic condition that can have a negative impact on one’s health and even result in mortality. The management of obesity has been addressed in a number...
Conclusions/Relevance: Many clinical studies have revealed that some antihyperglycemic medications can help people lose weight, while others either cause weight gain or neutral results. Acarbose has mild weight loss effects and metformin and sodium-dependent glucose cotransporter proteins-2 (SGLT-2) inhibitors have modest weight loss effects;...
Share
Semaglutide for the treatment of antipsychotic-associated weight gain in patients not responding to metformin - a case series - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/37113745/
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site. The site is secure....
Conclusions/Relevance: Initial evidence from our real-world clinical setting suggests that semaglutide may be effective in reducing AAWG in patients not responding to metformin. Randomized control trials investigating semaglutide for AAWG are needed to corroborate these findings.
Share
Semaglutide-eye-catching results
Source : https://www.wjgnet.com/1948-9358/full/v14/i4/424.htm
Glucagon-like peptide-1 receptor agonists (GLP-1RA) are a class of drugs increasingly used for the treatment of patients with type 2 diabetes mellitus (T2DM), enhancing glucose management while promoting weight loss...
Core Tip: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) benefit patients with type 2 diabetes mellitus in terms of glucose management, weight control, oxidative damage, and prevention of adverse renal and cardiovascular events without increasing the of risk of hypoglycemia. After reviewing the literature to investigate upon such a...
Share
Combination Therapy of Metformin and p-Coumaric Acid Mitigates Metabolic Dysfunction Associated with Obesity and Non-Alcoholic Fatty Liver Disease in High-Fat Diet Obese C57BL/6 Mice
Source : https://www.sciencedirect.com/science/article/abs/pii/S095528632300102X?via=ihub
Available online 25 April 2023, 109369 Author links open overlay panel, , , , Reza Meshkani 1 Show more Metformin (MET) has been demonstrated to have favorable impact on nonalcoholic...
Conclusions/Relevance: Taken together, these findings indicate that MET combined with PCA can improve NAFLD through decreasing lipid accumulation, inhibiting inflammation and inducing thermogenesis, and adipose tissue browning.
Share